LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biogen Inc. (NASDAQ: BIIB), following which we have published ...
Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF ...
IMRALDI has been developed by Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen (NASDAQ, BIIB) and is approved for the treatment of rheumatoid arthritis (RA), juvenile idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback